Oncohost
Leveraging proteomic pattern analysis to personalize cancer treatment and improve patient outcomes.
About
Technology stack
detected 2026-06-19No comments yet. Be the first to share your take.
What does Oncohost do?
OncoHost's PROphet® platform uses bioinformatic proteomic pattern recognition and AI to generate a personalized PROphet® score, predicting the benefit of PD-1/PD-L1 inhibitors. This blood-based test provides an all-inclusive evaluation of the tumor and host microenvironment to aid clinical decision-making and improve patient outcomes. The company serves patients, providers, and pharmaceutical partners.
How much funding has Oncohost raised?
Oncohost has raised a total of $43M in funding. The most recent round on record is Series C.
Where is Oncohost headquartered?
Oncohost is headquartered in Tel Aviv, Israel.
When was Oncohost founded?
Oncohost was founded in 2017.
What industry does Oncohost operate in?
Oncohost operates in Healthcare, Pharmaceutical, Oncology, Cancer, Proteomics, HealthTech.
How many employees does Oncohost have?
Oncohost has approximately 46 people on record.